nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0205	0.0317	CcSEcCtD
Nefazodone—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0232	CcSEcCtD
Nefazodone—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0198	CcSEcCtD
Nefazodone—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0175	CcSEcCtD
Nefazodone—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0173	CcSEcCtD
Nefazodone—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0167	CcSEcCtD
Nefazodone—Gout—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0166	CcSEcCtD
Nefazodone—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0164	CcSEcCtD
Nefazodone—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.0103	0.0158	CcSEcCtD
Nefazodone—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00921	0.0142	CcSEcCtD
Nefazodone—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00911	0.014	CcSEcCtD
Nefazodone—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00911	0.014	CcSEcCtD
Nefazodone—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00833	0.0128	CcSEcCtD
Nefazodone—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00825	0.0127	CcSEcCtD
Nefazodone—Aripiprazole—CHRM3—nephrolithiasis	0.00802	0.615	CrCbGaD
Nefazodone—Injury—Hydrochlorothiazide—nephrolithiasis	0.00796	0.0123	CcSEcCtD
Nefazodone—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00789	0.0122	CcSEcCtD
Nefazodone—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00778	0.012	CcSEcCtD
Nefazodone—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00772	0.0119	CcSEcCtD
Nefazodone—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00769	0.0118	CcSEcCtD
Nefazodone—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00753	0.0116	CcSEcCtD
Nefazodone—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00734	0.0113	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00731	0.0113	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00726	0.0112	CcSEcCtD
Nefazodone—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0072	0.0111	CcSEcCtD
Nefazodone—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0072	0.0111	CcSEcCtD
Nefazodone—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00706	0.0109	CcSEcCtD
Nefazodone—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00693	0.0107	CcSEcCtD
Nefazodone—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00688	0.0106	CcSEcCtD
Nefazodone—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00675	0.0104	CcSEcCtD
Nefazodone—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0067	0.0103	CcSEcCtD
Nefazodone—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00668	0.0103	CcSEcCtD
Nefazodone—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00659	0.0101	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00659	0.0101	CcSEcCtD
Nefazodone—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00647	0.00997	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00645	0.00994	CcSEcCtD
Nefazodone—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00636	0.0098	CcSEcCtD
Nefazodone—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00632	0.00974	CcSEcCtD
Nefazodone—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00632	0.00974	CcSEcCtD
Nefazodone—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00616	0.00949	CcSEcCtD
Nefazodone—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00591	0.00911	CcSEcCtD
Nefazodone—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00584	0.009	CcSEcCtD
Nefazodone—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00582	0.00897	CcSEcCtD
Nefazodone—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00577	0.00889	CcSEcCtD
Nefazodone—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00575	0.00886	CcSEcCtD
Nefazodone—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00567	0.00873	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00559	0.00861	CcSEcCtD
Nefazodone—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00548	0.00844	CcSEcCtD
Nefazodone—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00548	0.00844	CcSEcCtD
Nefazodone—HTR2A—urine—nephrolithiasis	0.00542	0.101	CbGeAlD
Nefazodone—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0054	0.00832	CcSEcCtD
Nefazodone—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00537	0.00828	CcSEcCtD
Nefazodone—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00532	0.00819	CcSEcCtD
Nefazodone—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00529	0.00815	CcSEcCtD
Nefazodone—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00794	CcSEcCtD
Nefazodone—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00507	0.00782	CcSEcCtD
Nefazodone—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00506	0.0078	CcSEcCtD
Nefazodone—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00776	CcSEcCtD
Nefazodone—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00502	0.00774	CcSEcCtD
Nefazodone—CYP3A4—urine—nephrolithiasis	0.00501	0.0932	CbGeAlD
Nefazodone—Quetiapine—CHRM3—nephrolithiasis	0.00501	0.385	CrCbGaD
Nefazodone—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00498	0.00768	CcSEcCtD
Nefazodone—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00496	0.0175	CbGpPWpGaD
Nefazodone—CYP2D6—urine—nephrolithiasis	0.00493	0.0918	CbGeAlD
Nefazodone—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00493	0.0173	CbGpPWpGaD
Nefazodone—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00488	0.00751	CcSEcCtD
Nefazodone—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00482	0.017	CbGpPWpGaD
Nefazodone—HTR1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00479	0.0169	CbGpPWpGaD
Nefazodone—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00478	0.00737	CcSEcCtD
Nefazodone—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00477	0.0168	CbGpPWpGaD
Nefazodone—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00472	0.00727	CcSEcCtD
Nefazodone—Flushing—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00723	CcSEcCtD
Nefazodone—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00461	0.0162	CbGpPWpGaD
Nefazodone—ADRA1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00457	0.0161	CbGpPWpGaD
Nefazodone—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00448	0.0158	CbGpPWpGaD
Nefazodone—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00447	0.00689	CcSEcCtD
Nefazodone—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00439	0.0155	CbGpPWpGaD
Nefazodone—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.00435	0.0808	CbGeAlD
Nefazodone—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00434	0.00669	CcSEcCtD
Nefazodone—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00665	CcSEcCtD
Nefazodone—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00426	0.00656	CcSEcCtD
Nefazodone—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00423	0.00652	CcSEcCtD
Nefazodone—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00415	0.0064	CcSEcCtD
Nefazodone—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00414	0.0146	CbGpPWpGaD
Nefazodone—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00413	0.00636	CcSEcCtD
Nefazodone—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00409	0.0063	CcSEcCtD
Nefazodone—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00408	0.0144	CbGpPWpGaD
Nefazodone—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00627	CcSEcCtD
Nefazodone—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00406	0.0143	CbGpPWpGaD
Nefazodone—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00405	0.00624	CcSEcCtD
Nefazodone—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00402	0.0062	CcSEcCtD
Nefazodone—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00397	0.00612	CcSEcCtD
Nefazodone—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00396	0.0061	CcSEcCtD
Nefazodone—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00395	0.00609	CcSEcCtD
Nefazodone—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00394	0.00607	CcSEcCtD
Nefazodone—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00389	0.006	CcSEcCtD
Nefazodone—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00387	0.00596	CcSEcCtD
Nefazodone—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00387	0.0136	CbGpPWpGaD
Nefazodone—Cough—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00592	CcSEcCtD
Nefazodone—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00377	0.0133	CbGpPWpGaD
Nefazodone—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00578	CcSEcCtD
Nefazodone—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00578	CcSEcCtD
Nefazodone—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00578	CcSEcCtD
Nefazodone—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00576	CcSEcCtD
Nefazodone—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.00372	0.0692	CbGeAlD
Nefazodone—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.0037	0.00571	CcSEcCtD
Nefazodone—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00565	CcSEcCtD
Nefazodone—ADRA1B—renal system—nephrolithiasis	0.00365	0.0678	CbGeAlD
Nefazodone—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00362	0.00558	CcSEcCtD
Nefazodone—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00359	0.00554	CcSEcCtD
Nefazodone—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00359	0.00554	CcSEcCtD
Nefazodone—Shock—Hydrochlorothiazide—nephrolithiasis	0.00354	0.00545	CcSEcCtD
Nefazodone—ADRA1B—kidney—nephrolithiasis	0.00353	0.0656	CbGeAlD
Nefazodone—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00542	CcSEcCtD
Nefazodone—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00541	CcSEcCtD
Nefazodone—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00348	0.00535	CcSEcCtD
Nefazodone—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00343	0.00528	CcSEcCtD
Nefazodone—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00336	0.00518	CcSEcCtD
Nefazodone—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00333	0.0117	CbGpPWpGaD
Nefazodone—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00332	0.0117	CbGpPWpGaD
Nefazodone—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00505	CcSEcCtD
Nefazodone—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00501	CcSEcCtD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00325	0.0114	CbGpPWpGaD
Nefazodone—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00323	0.00497	CcSEcCtD
Nefazodone—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.0032	0.00494	CcSEcCtD
Nefazodone—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0032	0.00492	CcSEcCtD
Nefazodone—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00316	0.00488	CcSEcCtD
Nefazodone—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00481	CcSEcCtD
Nefazodone—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00474	CcSEcCtD
Nefazodone—Pain—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00474	CcSEcCtD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00297	0.0105	CbGpPWpGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00297	0.0105	CbGpPWpGaD
Nefazodone—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00296	0.00456	CcSEcCtD
Nefazodone—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00296	0.0104	CbGpPWpGaD
Nefazodone—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00294	0.0104	CbGpPWpGaD
Nefazodone—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00453	CcSEcCtD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00288	0.0101	CbGpPWpGaD
Nefazodone—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00286	0.0044	CcSEcCtD
Nefazodone—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00438	CcSEcCtD
Nefazodone—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00438	CcSEcCtD
Nefazodone—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00408	CcSEcCtD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00263	0.00927	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00263	0.00927	CbGpPWpGaD
Nefazodone—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00397	CcSEcCtD
Nefazodone—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00254	0.00392	CcSEcCtD
Nefazodone—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00379	CcSEcCtD
Nefazodone—HTR1A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00243	0.00855	CbGpPWpGaD
Nefazodone—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00366	CcSEcCtD
Nefazodone—CYP3A7—Biological oxidations—SLC26A1—nephrolithiasis	0.00235	0.00828	CbGpPWpGaD
Nefazodone—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00352	CcSEcCtD
Nefazodone—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.00228	0.00801	CbGpPWpGaD
Nefazodone—Rash—Hydrochlorothiazide—nephrolithiasis	0.00227	0.00349	CcSEcCtD
Nefazodone—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00349	CcSEcCtD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00225	0.00793	CbGpPWpGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00225	0.00793	CbGpPWpGaD
Nefazodone—Headache—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00347	CcSEcCtD
Nefazodone—HTR1A—renal system—nephrolithiasis	0.00222	0.0414	CbGeAlD
Nefazodone—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00219	0.0077	CbGpPWpGaD
Nefazodone—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00329	CcSEcCtD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00209	0.00737	CbGpPWpGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00209	0.00737	CbGpPWpGaD
Nefazodone—ADRA1A—renal system—nephrolithiasis	0.00205	0.0381	CbGeAlD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.002	0.00703	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.002	0.00703	CbGpPWpGaD
Nefazodone—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00196	0.0069	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00191	0.00672	CbGpPWpGaD
Nefazodone—ADRA1B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00188	0.0066	CbGpPWpGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00187	0.00657	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00186	0.00653	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00186	0.00653	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00185	0.00652	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00185	0.00652	CbGpPWpGaD
Nefazodone—CYP3A5—nephron tubule—nephrolithiasis	0.0018	0.0334	CbGeAlD
Nefazodone—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00179	0.0063	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00175	0.00617	CbGpPWpGaD
Nefazodone—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.0017	0.00599	CbGpPWpGaD
Nefazodone—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0017	0.00599	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00168	0.0059	CbGpPWpGaD
Nefazodone—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00167	0.00586	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00165	0.00582	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00165	0.00581	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00164	0.00578	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00164	0.00578	CbGpPWpGaD
Nefazodone—CYP3A5—renal system—nephrolithiasis	0.00163	0.0304	CbGeAlD
Nefazodone—ADRA1B—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00163	0.00572	CbGpPWpGaD
Nefazodone—CYP3A5—kidney—nephrolithiasis	0.00158	0.0294	CbGeAlD
Nefazodone—CYP3A5—cortex of kidney—nephrolithiasis	0.00154	0.0286	CbGeAlD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00152	0.00536	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00151	0.00532	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00151	0.00532	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00149	0.00524	CbGpPWpGaD
Nefazodone—ADRA2A—cortex of kidney—nephrolithiasis	0.00147	0.0273	CbGeAlD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00146	0.00515	CbGpPWpGaD
Nefazodone—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00144	0.00508	CbGpPWpGaD
Nefazodone—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00142	0.00499	CbGpPWpGaD
Nefazodone—ADRA1B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00136	0.00477	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00135	0.00477	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00134	0.00471	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00134	0.00471	CbGpPWpGaD
Nefazodone—HTR2A—renal system—nephrolithiasis	0.00133	0.0246	CbGeAlD
Nefazodone—HTR2A—kidney—nephrolithiasis	0.00128	0.0238	CbGeAlD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00127	0.00446	CbGpPWpGaD
Nefazodone—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00123	0.00433	CbGpPWpGaD
Nefazodone—CYP3A4—renal system—nephrolithiasis	0.00123	0.0228	CbGeAlD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00121	0.00427	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00121	0.00426	CbGpPWpGaD
Nefazodone—CYP2D6—renal system—nephrolithiasis	0.00121	0.0225	CbGeAlD
Nefazodone—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0012	0.00424	CbGpPWpGaD
Nefazodone—CYP3A4—kidney—nephrolithiasis	0.00119	0.0221	CbGeAlD
Nefazodone—CYP2D6—kidney—nephrolithiasis	0.00117	0.0217	CbGeAlD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00115	0.00403	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00115	0.00403	CbGpPWpGaD
Nefazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0011	0.00387	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0011	0.00387	CbGpPWpGaD
Nefazodone—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00109	0.00385	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00108	0.00379	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00106	0.00375	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00106	0.00375	CbGpPWpGaD
Nefazodone—ADRA1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00105	0.00369	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00101	0.00357	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00101	0.00357	CbGpPWpGaD
Nefazodone—ABCB1—nephron tubule—nephrolithiasis	0.000955	0.0178	CbGeAlD
Nefazodone—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000951	0.00335	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000949	0.00334	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000949	0.00334	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000943	0.00332	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000943	0.00332	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000943	0.00332	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000938	0.0033	CbGpPWpGaD
Nefazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000931	0.00328	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000898	0.00316	CbGpPWpGaD
Nefazodone—ABCB1—renal system—nephrolithiasis	0.000869	0.0161	CbGeAlD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000865	0.00304	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000841	0.00296	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000841	0.00296	CbGpPWpGaD
Nefazodone—ABCB1—kidney—nephrolithiasis	0.00084	0.0156	CbGeAlD
Nefazodone—HTR1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000831	0.00292	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000827	0.00291	CbGpPWpGaD
Nefazodone—ABCB1—cortex of kidney—nephrolithiasis	0.000818	0.0152	CbGeAlD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000816	0.00287	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000816	0.00287	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000815	0.00287	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000798	0.00281	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.000791	0.00279	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000791	0.00278	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000759	0.00267	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—RGS14—nephrolithiasis	0.000755	0.00266	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000751	0.00264	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000741	0.00261	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000727	0.00256	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—RGS14—nephrolithiasis	0.000719	0.00253	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000718	0.00253	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000718	0.00253	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000714	0.00251	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000703	0.00247	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.000698	0.00246	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.000698	0.00246	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.000684	0.00241	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000672	0.00237	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000665	0.00234	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000665	0.00234	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—PTH—nephrolithiasis	0.000657	0.00231	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000653	0.0023	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000653	0.0023	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.000652	0.00229	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.000638	0.00225	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—PTH—nephrolithiasis	0.000625	0.0022	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00062	0.00218	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000607	0.00214	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.000593	0.00209	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000567	0.002	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000564	0.00199	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000561	0.00198	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000558	0.00197	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.000556	0.00196	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.000535	0.00188	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GRHPR—nephrolithiasis	0.000531	0.00187	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000524	0.00185	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000522	0.00184	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.000516	0.00182	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DGKH—nephrolithiasis	0.00051	0.00179	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000507	0.00178	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000504	0.00177	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000504	0.00177	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADCY10—nephrolithiasis	0.000499	0.00176	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DGKH—nephrolithiasis	0.000485	0.00171	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000485	0.00171	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000475	0.00167	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AGXT—nephrolithiasis	0.000473	0.00167	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000469	0.00165	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000469	0.00165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000453	0.00159	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RGS14—nephrolithiasis	0.000446	0.00157	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000443	0.00156	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000443	0.00156	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000441	0.00155	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00044	0.00155	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.000431	0.00152	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RGS14—nephrolithiasis	0.000424	0.00149	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.000419	0.00147	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000418	0.00147	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000418	0.00147	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000412	0.00145	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000406	0.00143	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000404	0.00142	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—APRT—nephrolithiasis	0.000403	0.00142	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—SLC26A1—nephrolithiasis	0.000403	0.00142	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000401	0.00141	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000386	0.00136	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.000385	0.00136	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GRHPR—nephrolithiasis	0.000384	0.00135	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.000377	0.00133	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.000373	0.00131	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000371	0.00131	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000369	0.0013	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000368	0.0013	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000367	0.00129	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PTH—nephrolithiasis	0.000353	0.00124	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000351	0.00124	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000351	0.00123	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.00035	0.00123	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000343	0.00121	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AGXT—nephrolithiasis	0.000342	0.0012	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PTH—nephrolithiasis	0.000337	0.00119	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.000335	0.00118	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000334	0.00118	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PTH—nephrolithiasis	0.000321	0.00113	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000321	0.00113	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000319	0.00112	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000318	0.00112	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APRT—nephrolithiasis	0.000318	0.00112	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.000318	0.00112	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000314	0.0011	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000312	0.0011	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000301	0.00106	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DGKH—nephrolithiasis	0.000301	0.00106	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.0003	0.00105	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.0003	0.00105	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000292	0.00103	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000291	0.00102	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APRT—nephrolithiasis	0.000291	0.00102	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	0.000291	0.00102	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.00029	0.00102	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00029	0.00102	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AQP1—nephrolithiasis	0.000287	0.00101	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000287	0.00101	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DGKH—nephrolithiasis	0.000287	0.00101	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.000285	0.001	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000273	0.000961	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.000265	0.000932	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.00026	0.000916	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00026	0.000916	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CHRM3—nephrolithiasis	0.000259	0.000913	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000258	0.000909	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.000255	0.000896	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000255	0.000896	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000243	0.000856	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.000237	0.000833	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000237	0.000833	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.000226	0.000796	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APRT—nephrolithiasis	0.00022	0.000773	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.00022	0.000773	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000218	0.000766	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000217	0.000762	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AQP1—nephrolithiasis	0.000207	0.00073	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000207	0.00073	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000207	0.000728	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000207	0.000728	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.000205	0.00072	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTH—nephrolithiasis	0.000199	0.000701	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000198	0.000697	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTH—nephrolithiasis	0.00019	0.000667	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000188	0.000662	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CHRM3—nephrolithiasis	0.000187	0.00066	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000184	0.000648	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000178	0.000628	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000172	0.000605	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000171	0.000602	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000168	0.000593	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000159	0.00056	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000156	0.000551	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000156	0.000551	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000147	0.000519	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000141	0.000498	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000135	0.000476	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000135	0.000476	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000133	0.000469	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SPP1—nephrolithiasis	9.99e-05	0.000352	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	9.94e-05	0.00035	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AQP1—nephrolithiasis	9.64e-05	0.000339	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SPP1—nephrolithiasis	9.52e-05	0.000335	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CHRM3—nephrolithiasis	8.72e-05	0.000307	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	8.63e-05	0.000304	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	8.45e-05	0.000298	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	7.86e-05	0.000276	CbGpPWpGaD
